Loading...
You have changed your country from
to
. Please be aware that this will change the currency in the purchasing process.
Products:Cardiovascular >> Angiogenesis >> Adhesion / ECM >> Matrix Metalloproteinases >> MMP
Overview
Product name
Anti-MMP9 antibody - Carboxyterminal end
See all MMP9 products (27) ...
Description
Rabbit polyclonal to MMP9 - Carboxyterminal end
Specificity
This antibody binds to both reduced and non reduced MMP9 proteins. It does not cross react with the other MMP family members (MMP1, MMP2, MMP3).
Tested applications
WB, ICC/IFmore details
Cross reactivity
Reacts with
Human
Immunogen
The details of the immunogen for this antibody are not available. (Human)(Peptide available as ab41067.)
Positive control
Cell media from human chondrosarcoma.
Properties
Form
Liquid
Storage instructions
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze / thaw cycles.
Storage buffer
Preservative: 0.05% Sodium Azide
Constituents: 50% Glycerol
Concentration
Concentration information loading...
Purity
Immunogen affinity purified
Purification notes
The antibody has been peptide affinity purified.
Clonality
Polyclonal
Isotype
IgG
Research areas
Cardiovascular >> Atherosclerosis >> Thrombosis >> Other
Cancer >> Tumor biomarkers >> Enzymes >> MMPs
Cell Biology >> Proteolysis / Ubiquitin >> Proteolytic enzymes >> Metalloprotease >> MMPs
Cancer >> Invasion/microenvironment >> ECM >> Extracellular matrix >> MMPs
Cancer >> Invasion/microenvironment >> Angiogenesis >> ECM enzymes >> MMPs
Signal Transduction >> Cytoskeleton / ECM >> Extracellular Matrix >> ECM Enzymes >> MMP
Cardiovascular >> Angiogenesis >> Adhesion / ECM >> Matrix Metalloproteinases >> MMP
Applications
Show applications key
Our Abpromise guarantee covers the use of ab38906 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notes
ICC/IF: Use at a concentration of 1 µg/ml.
WB: 1/1000 (when using colorimetric substrates such as BCIP/NBT) - 1/5000 (for chemiluminescent substrates). Detects a band of approximately 95 kDa. Dilution optimised using Chromogenic detection.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Target
Function
May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-
-Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide.
Tissue specificity
Produced by normal alveolar macrophages and granulocytes.
Involvement in disease
Defects in MMP9 may be a cause of susceptibility to intervertebral disc disease (IDD) [MIM:603932]; also known as lumbar disk herniation (LDH). IDD is one of the most common musculo-skeletal disorders and the predominant cause of low-back pain and unilateral leg pain.
Defects in MMP9 are the cause of metaphyseal anadysplasia type 2 (MANDP2) [MIM:613073]. Metaphyseal anadysplasia consists of an abnormal bone development characterized by severe skeletal changes that, in contrast with the progressive course of most other skeletal dysplasias, resolve spontaneously with age. Clinical characteristics are evident from the first months of life and include slight shortness of stature and a mild varus deformity of the legs. Patients attain a normal stature in adolescence and show improvement or complete resolution of varus deformity of the legs and rhizomelic micromelia.
Sequence similarities
Belongs to the peptidase M10A family.
Contains 3 fibronectin type-II domains.
Contains 4 hemopexin-like domains.
Domain
The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
Post-translational
modifications
Processing of the precursor yields different active forms of 64, 67 and 82 kDa. Sequentially processing by MMP3 yields the 82 kDa matrix metalloproteinase-9.
N- and O-glycosylated.
Cellular localization
Secreted > extracellular space > extracellular matrix.
Target information above from: UniProt accessionP14780
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
Alternative names
- 82 kDa matrix metalloproteinase-9 antibody
- 92 kDa gelatinase antibody
- 92 kDa type IV collagenase antibody
see all
Database links
- Entrez Gene: 4318 Human
- Omim: 120361 Human
- SwissProt: P14780 Human
- Unigene: 297413 Human
Anti-MMP9 antibody - Carboxyterminal end images:
Western blot - MMP9 antibody - Carboxyterminal end (ab38906)
All lanes : Anti-MMP9 antibody - Carboxyterminal end (ab38906) at 1/1000 dilution
Lane 1 : Human MMP9
Lane 2 : Cell media from human chondrosarcoma (untreated)
Observed band size : 97 kDa (why is the actual band size different from the predicted?)
When used against the reduced protein, this antibody identifies bands at 92 kDa and 88 kDa (the pro form and active form).
Immunocytochemistry/ Immunofluorescence - MMP9 antibody - Carboxyterminal end (ab38906)
ICC/IF image of ab38906 stained HeLa cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab38906, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
Protocols
References for Anti-MMP9 antibody - Carboxyterminal end (ab38906)
This product has been referenced in:
- Lluri Get al. Tissue inhibitor of metalloproteinase-2 (TIMP-2) regulates myogenesis and beta1 integrin expression in vitro. Exp Cell Res 314:11-24 (2008). WB, ICC/IF; Mouse.Read more (PubMed: 17678891) »
See 1 publication for this product
Publishing research using ab38906? Please let us know so that we can cite the reference in this datasheet
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"